XEN1101 as Adjunctive Therapy in Focal Epilepsy

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy.

Inclusion Criteria:
Patient must be 18 Years to 75 Years old.
Be properly informed of the nature and risks of the study and give informed consent in writing, prior to entering the study
BMI <35 kg/m2
Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy [ILAE] Classification of Epilepsy (2017)
Treatment with a stable dose of 1 to 3 allowable current AEDs for at least one month prior to screening, during baseline, and throughout the duration of the study
Must be willing to comply with the contraception requirements
Able to keep accurate seizure diaries